NEW YORK, April 24, 2017 /PRNewswire/ --
Pre-market, Stock-Callers.com has initiated reports coverage on four major players in the Drug Manufacturers industry, and they are: Bristol-Myers Squibb Co. (NYSE: BMY), AstraZeneca PLC (NYSE: AZN), Eli Lilly and Co. (NYSE: LLY), and Immune Pharmaceuticals Inc. (NASDAQ: IMNP). As per an Euler Hermes report, the global prescription drug market is expected to rise to $810 billion this year, up from the estimated $780 billion in 2016. You can access our complimentary research reports on these stocks now at:
New York headquartered Bristol-Myers Squibb Co.'s stock finished last Friday's session 0.07% higher at $53.48. A total volume of 5.22 million shares was traded. The Company's shares have advanced 9.42% over the previous three months. The stock is trading below its 50-day moving average by 2.36%. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have a Relative Strength Index (RSI) of 43.34.
On April 17th, 2017, Bristol-Myers Squibb and Nordic Bioscience, a Danish company specializing in biomarker technologies, announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis. A biomarker is a molecule that may be used to diagnose a disease, or predict disease progression, and indicate response to therapy. Visit us today and download your complete report on BMY for free at:
On Friday, shares in Cambridge, the UK headquartered AstraZeneca PLC ended the session 0.47% lower at $29.76. The stock recorded a trading volume of 2.04 million shares. The Company's shares have gained 13.58% in the previous three months and 12.54% on an YTD basis. The stock is trading 1.60% above its 200-day moving average. Moreover, shares of AstraZeneca, which engages in the discovery, development, manufacture, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide, have an RSI of 41.18.
On March 28th, 2017, AstraZeneca announced that the US FDA has accepted the Company's New Drug Application for LYNPARZA™ (olaparib) tablets (300mg twice daily) for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting. The FDA has also granted priority review status with a Prescription Drug User Fee Act set for Q3 2017.
On April 10th, 2017, research firm Jefferies downgraded the Company's stock rating from 'Buy' to 'Hold'. The complimentary research report on AZN can be accessed at:
Indianapolis, Indiana headquartered Eli Lilly and Co.'s shares declined 0.06%, closing the session at $81.89 with a total trading volume of 3.20 million shares. The stock has gained 7.33% over the previous three months and 12.09% on an YTD basis. The Company's shares are trading 5.12% above their 200-day moving average. Additionally, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 40.43.
On April 14th, 2017, Eli Lilly and Incyte Corporation announced that the US FDA has issued a complete response letter for the New Drug Application of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis. The letter indicates that the FDA is unable to approve the application in its current form, and that additional clinical data are needed to determine the most appropriate doses.
On April 17th, 2017, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'. Register for free on Stock-Callers.com and download the PDF research report on LLY at:
Last Friday at the close, shares in New York headquartered Immune Pharmaceuticals Inc. recorded a trading volume of 999,258 shares. The stock ended the session 3.29% lower at $3.53. Furthermore, shares of Immune Pharma, which develops and commercializes novel targeted therapeutics in the immuno-inflammation and immuno-oncology areas, have an RSI of 88.56.
On April 20th, 2017, Immune Pharma announced that it has entered into a letter of intent with Pint Pharma GmnH ("Pint"), a pharmaceutical company focused on Latin America and other markets, which binds the parties to seek agreement regarding an exclusive license by Pint of the rights to commercialize Ceplene throughout Latin America, including Argentina, Brazil, Chile, Colombia, and Mexico. The duo targets closing a final agreement within 30 days. Get free access to your research report on IMNP at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA